Efficacy and Safety of Belimumab in Patients With Lupus Nephritis: Subgroup Analyses of a Phase 3 Randomized Trial in the East Asian Population
Xueqing Yu,Nan Chen,Jun Xue,Chi Chiu Mok,Sang-Cheol Bae,Xiaomei Peng,Wei Chen,Hong Ren,Xiao Li,Kajohnsak Noppakun,Yulia Green,Beulah Ji,Chang Liu,Anuradha Madan,Mohamed Okily,Chun-Hang Tang,Jennifer A. Gilbride,David A. Roth
DOI: https://doi.org/10.1053/j.ajkd.2022.06.013
IF: 11.072
2023-03-01
American Journal of Kidney Diseases
Abstract:RATIONALE & OBJECTIVE: <AbstractText Label="RATIONALE & OBJECTIVE">Belimumab improved kidney outcomes in patients with active lupus nephritis (LN) in BLISS-LN, leading to its approval in the United States and the European Union. As data on treatment of East Asian patients with LN are limited, we evaluated the efficacy and safety of belimumab in the BLISS-LN East Asian subgroup.</AbstractText>STUDY DESIGN: <AbstractText Label="STUDY DESIGN">Prespecified subgroup analysis of BLISS-LN, a phase 3, placebo-controlled, randomized 104-week trial.</AbstractText>SETTING & PARTICIPANTS: <AbstractText Label="SETTING & PARTICIPANTS">Adults with biopsy-proven, active LN were randomized (1:1) to belimumab or placebo, plus standard therapy.</AbstractText>INTERVENTION: <AbstractText Label="INTERVENTION">Patients were administered intravenous belimumab 10mg/kg, or placebo, plus standard therapy (oral glucocorticoids and either cyclophosphamide for induction followed by azathioprine for maintenance, or mycophenolate mofetil for both induction and maintenance). At the investigator's discretion, 1-3 intravenous pulses of methylprednisolone, 500-1,000mg each, could be administered during induction.</AbstractText>OUTCOMES: <AbstractText Label="OUTCOMES">The primary end point was primary efficacy renal response (PERR; ie, urinary protein-creatinine ratio≤0.7g/g, estimated glomerular filtration rate no more than 20% below preflare value or≥60mL/min/1.73m<sup>2</sup>, and no treatment failure) at week 104. Key secondary end points included complete renal response (CRR; urinary protein-creatinine ratio<0.5g/g, estimated glomerular filtration rate no more than 10% below preflare value or≥90mL/min/1.73m<sup>2</sup>, and no treatment failure) at week 104; PERR at week 52; time to kidney-related event or death; and safety.</AbstractText>ANALYTICAL APPROACH: <AbstractText Label="ANALYTICAL APPROACH">PERR and CRR were analyzed using a logistic regression model, and time to a kidney-related event or death was analyzed using a Cox proportional hazards regression model.</AbstractText>RESULTS: <AbstractText Label="RESULTS">142 patients from mainland China, Hong Kong, South Korea, and Taiwan were included (belimumab, n=74; placebo, n=68). At week 104, more belimumab than placebo patients achieved PERR (53% vs 37%; OR, 1.76 [95% CI, 0.88-3.51]) and CRR (35% vs 25%; OR, 1.73 [95% CI, 0.80-3.74]). At week 52, more belimumab than placebo patients achieved PERR (62% vs 37%; OR, 2.74 [95% CI, 1.33-5.64]). Belimumab reduced the risk of a kidney-related event or death compared with placebo at any time (HR, 0.37 [95% CI, 0.15-0.91]). Safety was similar across treatment groups.</AbstractText>LIMITATIONS: <AbstractText Label="LIMITATIONS">Small sample size and lack of formal significance testing.</AbstractText>CONCLUSIONS: <AbstractText Label="CONCLUSIONS">Safety and efficacy profiles were consistent with BLISS-LN overall population, supporting benefits of belimumab treatment in the East Asian subgroup with LN.</AbstractText>FUNDING: <AbstractText Label="FUNDING">This study was funded by GSK (GSK study no. BEL114054).</AbstractText>TRIAL REGISTRATION: <AbstractText Label="TRIAL REGISTRATION">Registered at ClinicalTrials.gov with study number NCT01639339.</AbstractText>
urology & nephrology